Related Experiment Video
Updated: Aug 10, 2025
08:00
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
20.3K
Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells
Michael Chamo1, Omri Koren1, Oron Goldstein1
1The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer Shevap 8410501, Israel.
Cancers
|February 11, 2023
Summary
Researchers identified leukemic stem cells (LSCs) in a syngeneic mouse model, crucial for Acute Myeloid Leukemia (AML) relapse. These identified LSCs possess the ability to regenerate disease heterogeneity and express potential therapeutic targets.
Area of Science:
- Hematology
- Cancer Biology
- Immunology
Background:
- Acute Myeloid Leukemia (AML) is a serious cancer with high relapse rates, often linked to leukemic stem cells (LSCs).
- The existence and identification of LSCs are debated, particularly due to challenges in human cell xenotransplantation models.
- Investigating LSCs in immunocompetent models is essential for understanding AML relapse mechanisms.
Purpose of the Study:
- To identify and characterize LSCs within an immunocompetent syngeneic mouse model of AML.
- To investigate the role of specific cell surface markers in isolating LSC populations.
- To explore the gene expression profile of identified LSCs and their potential therapeutic implications.
Main Methods:
- Utilized the ML23 leukemia line, known for its phenotypic heterogeneity.
- Prospectively isolated a disease-relapsing sub-population using surface markers: cKit+, CD9-, CD48+, Mac1-/low.
- Transplanted the isolated sub-population into syngeneic hosts to assess disease relapse and heterogeneity restoration.
- Performed gene expression profiling to identify unique LSC signatures and therapeutic targets.
Main Results:
- Identified a distinct LSC sub-population (cKit+CD9-CD48+Mac1-/low) capable of inducing AML relapse in syngeneic hosts.
- Demonstrated that this LSC sub-population can restore the heterogeneity of the parental leukemia line upon transplantation.
- Detected the presence of LSCs in various organs within the murine model.
- Uncovered a unique gene expression signature for ML23 LSCs, including expression of therapeutic targets like CD47 and CD93.
Conclusions:
- Successfully identified and molecularly characterized LSCs in a syngeneic murine model, addressing limitations of previous studies.
- The identified LSC sub-population is capable of disease initiation and recapitulation of AML heterogeneity.
- The unique gene expression profile of these LSCs, including CD47 and CD93, offers potential avenues for targeted AML therapies.
